Vaccines Updates: Glioblastoma Breakthroughs, Oral Norovirus Vaccine, RSV Launch & More 🔬💉🌎
In this week’s edition of Vaccine Research Updates, we explore the most promising advances shaping global immunization and public health. From cutting-edge cancer vaccines to needle-free flu prevention and functional cures for hepatitis B, here’s what’s making headlines:
🧠SurVaxM Glioblastoma Vaccine advances as the Phase 2B SURVIVE trial meets all clinical benchmarks—patients showed a remarkable ninety-three point seven percent one-year survival rate compared to sixty-five percent historically.
🦠Vaxart’s oral norovirus vaccine proves successful in Phase 2 trials, with vaccinated groups experiencing thirty percent greater protection and eight point seven six times higher IgG antibody levels.
🌑 IO Biotech’s melanoma vaccine Cylembio stays on track for a 2026 launch, with Phase 3 results expected in Q3 2025 and strong investor backing confirmed through Q2 2026.
👃 AstraZeneca’s FluMist gains approval in South Korea—this needle-free nasal spray showed sixty-four percent real-world effectiveness and is particularly suitable for children.
🧓 GSK launches Arexvy, its RSV vaccine for adults aged sixty and above, in Korea—Phase 3 data revealed a ninety-four point one percent reduction in severe RSV-related lower respiratory tract disease.
🧬 Gilead’s hepatitis B vaccine candidates demonstrate strong T and B cell responses with minimal side effects, progressing toward a functional cure for chronic hepatitis B.
📢 Stay Ahead in Vaccine Research!
✅ Like, share, and subscribe for weekly updates on vaccine research
#VaccineInnovation #GlioblastomaVaccine #RSVVaccine #OralVaccines #FluMist #Gilead #HepatitisB #CancerVaccines #IOBiotech #SurVaxM #Norovirus #LucidQuest #VaccineUpdates #PublicHealth #ClinicalResearch #GlobalHealth #Immunization #PandemicPreparedness #BiotechNews #HealthcareInnovation